| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.70 [0.54, 0.90] | | < 1 | | 70% | 4 studies (4/-) | 99.7 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.59 [0.48, 0.71] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| PFS (extension) | 0.49 [0.41, 0.58] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.58 [0.53, 0.64] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DOR | 2.41 [1.27, 4.60] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.38 [1.78, 3.19] | | > 1 | | 59% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 3.57 [2.52, 5.06] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 4.04 [0.36, 44.82] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.03 [0.73, 1.45] | | < 1 | | 0% | 1 study (1/-) | 44.4 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.13 [0.56, 2.28] | | < 1 | | 0% | 1 study (1/-) | 36.6 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.19 [1.31, 3.65] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.04 [1.16, 3.59] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 3.47 [1.25, 9.62] | | < 1 | | 0% | 1 study (1/-) | 0.8 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 5.56 [1.49, 20.67] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.95 [0.29, 3.12] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 2.04 [0.92, 4.52] | | < 1 | | 0% | 1 study (1/-) | 4.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.52 [0.05, 5.86] | | < 1 | | 0% | 1 study (1/-) | 70.1 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.76 [0.25, 2.35] | | < 1 | | 0% | 1 study (1/-) | 68.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 4.44 [0.48, 40.91] | | < 1 | | 0% | 1 study (1/-) | 9.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 4.32 [0.19, 97.73] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.50 [0.03, 8.00] | | < 1 | | 0% | 1 study (1/-) | 68.7 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.79 [0.27, 2.29] | | < 1 | | 0% | 1 study (1/-) | 66.6 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 3.01 [0.15, 60.33] | | < 1 | | 0% | 1 study (1/-) | 23.8 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.00 [0.03, 29.86] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Dizziness TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 4.32 [0.19, 97.73] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.02 [0.21, 76.41] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.72 [0.04, 11.64] | | < 1 | | 0% | 2 studies (2/-) | 59.0 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.50 [0.01, 25.20] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.56 [0.14, 17.88] | | < 1 | | 0% | 2 studies (2/-) | 36.1 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.45 [0.13, 16.15] | | < 1 | | 0% | 2 studies (2/-) | 38.2 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.50 [0.01, 25.20] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 6.06 [0.34, 109.04] | | < 1 | | 0% | 1 study (1/-) | 11.3 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 2.14 [0.19, 24.25] | | < 1 | | 0% | 1 study (1/-) | 27.1 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.00 [0.09, 44.56] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.09 [0.35, 3.40] | | < 1 | | 0% | 2 studies (2/-) | 44.4 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.01 [0.33, 3.06] | | < 1 | | 0% | 2 studies (2/-) | 49.6 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.05 [0.14, 7.73] | | < 1 | | 0% | 1 study (1/-) | 48.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.50 [0.01, 25.20] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 1.07 [0.67, 1.71] | | < 1 | | 0% | 1 study (1/-) | 38.2 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.83 [0.78, 4.31] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 2.00 [0.22, 18.06] | | < 1 | | 0% | 1 study (1/-) | 26.9 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.50 [0.01, 25.20] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 3.02 [0.36, 25.28] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.79 [0.71, 4.50] | | < 1 | | 0% | 1 study (1/-) | 10.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.67 [0.30, 1.48] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 2.37 [0.89, 6.34] | | < 1 | | 0% | 1 study (1/-) | 4.3 % | NA | not evaluable | | non important | - |
| Lacrimation increased AE (grade 3-4) | 0.50 [0.01, 25.20] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.00 [0.40, 2.51] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.39 [0.84, 2.30] | | < 1 | | 0% | 1 study (1/-) | 9.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.00 [0.03, 29.86] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.00 [0.03, 29.86] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 1.17 [0.30, 4.56] | | < 1 | | 0% | 1 study (1/-) | 41.3 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.15 [0.60, 2.21] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.26 [0.48, 3.29] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
